BioCentury | Oct 17, 2020

Praxis sees strongest first-day among trio of IPOs as NASDAQ nears $16B raised in fresh paper

Among a trio of clinical biotechs pricing IPOs ahead of Friday’s NASDAQ session, demand was highest for Praxis as the company posted a 46% gain, while the reception was more muted for Aligos and Tarsus...
BioCentury | Oct 9, 2020

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...with idiopathic hypersomnia. Jazz plans to submit an sNDA as early as 1Q21 for the GABA B receptor...
BioCentury | Sep 25, 2020
Emerging Company Profile

XWPharma: timing therapy to biological rhythm’s other lead program, XW10172, is a GABA B receptor...
...Innovation – JJDC WI Harper Group WuXi AppTec KTB Network NMDA receptor GABA B receptor...
BioCentury | Sep 15, 2020

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

A Phase III readout that boosted Marinus’ value on Tuesday is the first in a series of upcoming milestones that could lead to the company carving out a commercial niche in rare seizure disorders. Trial...
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Inhibiting MAO-B or GABRA5 could treat subcortical stroke by restoring regional glucose metabolism and alleviating diaschisis, neurological dormancy at sites distant from a focal brain injury. In a rat model...
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

...or excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older. The GABA B receptor...
...lisocabtagene maraleucel, (JCAR017) Aurinia Pharmaceuticals Inc. Gruenenthal Group Averitas Pharma Inc. Mesoblast Ltd. Genfit S.A. Vertex Pharmaceuticals Inc. Bristol Myers Squibb Co. Interleukin-2 (IL-2) GABA B receptor Transient...
BioCentury | Jul 1, 2020
Emerging Company Profile

Engrail aims to build CNS pipeline by improving upon deprioritized assets

With a $32 million series A round from Nan Fung, Engrail expects to advance its first CNS program into the clinic by 1Q21 as it builds out a pipeline of neuroscience drugs via deals for...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in...
BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

Ovid’s gaboxadol meets in Phase II for Fragile X Ovid Therapeutics Inc. (NASDAQ:OVID) said gaboxadol (OV101) met its primary safety endpoint and reduced behavioral and functional symptoms in the Phase II ROCKET trial to treat...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...or excessive daytime sleepiness (EDS) in narcolepsy patients 7 years of age and older. The GABA B receptor...
...Pharmaceuticals Inc. Otsuka Pharmaceutical Co. Ltd. Merck KGaA Jazz Pharmaceuticals plc Forge Therapeutics Inc. Roche c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) GABA B receptor...
Items per page:
1 - 10 of 633